City of Hope and Imugene dose patient in Phase 1 trial to test cancer-killing oncolytic virus
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
The curriculum has been curated for General Physicians working in Clinikk
Surgical treatment of chronic pancreatitis is challenging in children and especially laparoscopic surgery has been rarely reported, worldwide
Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
Quantib Prostate is an AI-based software solution that advances the MRI prostate reporting workflow and is accessible directly from the radiologist's reading station
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
The drug will be available in 600 hospitals and 105 DTPs
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Subscribe To Our Newsletter & Stay Updated